Your browser is no longer supported. Please, upgrade your browser.
Settings
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E50.39 EPS (ttm)7.71 Insider Own1.40% Shs Outstand104.55M Perf Week4.96%
Market Cap40.62B Forward P/E25.30 EPS next Y15.35 Insider Trans-0.55% Shs Float78.08M Perf Month-1.43%
Income895.50M PEG2.75 EPS next Q3.07 Inst Own69.90% Short Float3.65% Perf Quarter12.12%
Sales4.86B P/S8.36 EPS this Y39.50% Inst Trans0.26% Short Ratio3.19 Perf Half Y7.00%
Book/sh42.33 P/B9.18 EPS next Y18.86% ROA13.80% Target Price416.43 Perf Year-0.72%
Cash/sh9.93 P/C39.10 EPS next 5Y18.31% ROE21.30% 52W Range325.35 - 452.96 Perf YTD5.83%
Dividend- P/FCF42.24 EPS past 5Y38.80% ROI18.20% 52W High-14.23% Beta1.41
Dividend %- Quick Ratio2.30 Sales past 5Y61.30% Gross Margin93.80% 52W Low19.41% ATR10.15
Employees5400 Current Ratio2.60 Sales Q/Q11.70% Oper. Margin27.40% RSI (14)59.39 Volatility3.00% 2.42%
OptionableYes Debt/Eq0.11 EPS Q/Q63.00% Profit Margin18.40% Rel Volume2.44 Prev Close366.62
ShortableYes LT Debt/Eq0.08 EarningsMay 04 BMO Payout0.00% Avg Volume892.65K Price388.49
Recom2.20 SMA203.69% SMA503.04% SMA2001.24% Volume2,179,500 Change5.97%
Mar-29-17Reiterated UBS Buy $435 → $446
Mar-17-17Initiated Oppenheimer Perform
Mar-09-17Initiated UBS Buy $435
Feb-16-17Downgrade Goldman Buy → Neutral
Jan-06-17Reiterated RBC Capital Mkts Outperform $626 → $598
Jan-06-17Reiterated Chardan Capital Markets Neutral $350 → $345
Dec-20-16Upgrade Credit Suisse Neutral → Outperform
Dec-12-16Upgrade Chardan Capital Markets Sell → Neutral $300 → $350
Nov-07-16Reiterated Chardan Capital Markets Sell $325 → $300
Aug-05-16Downgrade Robert W. Baird Outperform → Neutral $505 → $448
Jun-29-16Initiated Bernstein Outperform
Apr-20-16Downgrade Wells Fargo Outperform → Market Perform
Mar-28-16Reiterated Canaccord Genuity Hold $525 → $450
Mar-17-16Reiterated Sun Trust Rbsn Humphrey Neutral $450 → $410
Mar-16-16Downgrade Chardan Capital Markets Neutral → Sell $375 → $325
Mar-15-16Initiated Gabelli & Co Buy $574
Mar-03-16Initiated Sun Trust Rbsn Humphrey Neutral $450
Feb-25-16Initiated Citigroup Buy $480
Feb-16-16Upgrade Chardan Capital Markets Sell → Neutral $400 → $375
Feb-10-16Reiterated RBC Capital Mkts Outperform $676 → $668
Apr-28-17 05:46PM  Regeneron (REGN) to Post Q1 Earnings: What's in the Cards? Zacks +5.97%
10:43AM  Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Pick Up Zacks
09:57AM  Seattle Genetics (SGEN) Q1 Loss Widens, Sales Top Estimates Zacks
02:59AM  Genzyme, CHC lift Sanofi's first-quarter figures, upbeat on Dupixent Reuters
01:00AM  Regeneron and Sanofi Announce Kevzara® (sarilumab) Biologics License Application Resubmission Accepted for Review by U.S. FDA PR Newswire
Apr-27-17 09:21AM  Amgen's Q1 Results Highlight the Need for an Acquisition Motley Fool
09:08AM  Dupixent Expected to Be a Solid Addition to Regenerons Portfolio Market Realist
07:39AM  Analysts Recommendations for Regeneron in 1Q17 Market Realist
Apr-26-17 05:28PM  Amgen Trips Amid Rivals: Sales Miss By $100 Million, But Earnings Top Investor's Business Daily
04:33PM  Will Regenerons Revenue Surpass Analysts Estimates in 1Q17? Market Realist
01:35PM  Will Amgen's Rivals Pop On Its Cholesterol-Busting Drug? Investor's Business Daily
Apr-25-17 08:26AM  Earnings Preview: What To Expect From Amgen On Wednesday Forbes
08:00AM  Sanofi and Regeneron Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (alirocumab) Injection PR Newswire
08:00AM  Regeneron and Sanofi Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (alirocumab) Injection PR Newswire
Apr-24-17 01:00AM  Regeneron and Sanofi Receive Positive CHMP Opinion for Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis PR Newswire
Apr-21-17 04:15PM  Amgen Trumps Regeneron, Sanofi In Cholesterol Drug Sales Investor's Business Daily
02:22PM  EMA panel recommends nod for Sanofi, Regeneron's arthritis drug Reuters
Apr-20-17 09:31AM  Sanofi Genzyme hit with patent lawsuit over new eczema drug American City Business Journals
Apr-18-17 02:31PM  Could Lilly Outperform These Bigger Rivals On Strong Diabetes Meds? Investor's Business Daily
Apr-17-17 09:40AM  Lilly and Incyte's Loss Is AbbVie and Regeneron's Gain Motley Fool
Apr-16-17 02:02PM  3 Big Reasons to Be Bullish on Biotech Stocks Motley Fool
Apr-15-17 12:23AM  [$$] As Drug Prices Fall, These Stocks Could Rise Barrons.com
Apr-14-17 09:30AM  Regeneron to Report First Quarter 2017 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2017 PR Newswire
Apr-12-17 01:29PM  Regeneron Pharmaceuticals, Inc. Value Analysis (NASDAQ:REGN) : April 12, 2017 Capital Cube
12:51PM  How These Biotechs Could Save The Drug Sector In Q1 Or Not Investor's Business Daily
10:13AM  Don't Get Your Hopes Up For Biotech's Q1 Earnings Barrons.com
08:15AM  Blog Coverage Inotek Announces Completion of Recruitment in Phase-2 Study for Glaucoma Accesswire
07:36AM  Biotech Stock Roundup: Geron Gains on Interim Data, OncoMed Slumps on Pipeline Setback Zacks
Apr-11-17 04:24PM  Generics Set To Weaken This Drugmaker; Can MS Drugs Save It? Investor's Business Daily
08:42AM  Regeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : REGN-US : April 11, 2017 Capital Cube
Apr-08-17 04:11PM  3 Big Biotech Stocks With Big-Time Catalysts Motley Fool
Apr-07-17 10:36AM  Regeneron's Evinacumab Gets Breakthrough Therapy by FDA Zacks
Apr-06-17 12:16PM  Regeneron's Evinacumab Gets Breakthrough Designation Investopedia
11:23AM  Regeneron Science Talent Search to Ring The Nasdaq Stock Market Closing Bell GlobeNewswire
07:00AM  Regeneron Announces Evinacumab has Received FDA Breakthrough Therapy Designation for Homozygous Familial Hypercholesterolemia (HoFH) PR Newswire
Apr-04-17 11:45AM  Democrats found a way to speak Trump's language in pharma debate Yahoo Finance
Apr-03-17 11:00AM  Sarepta chief hands over CMO role to former Regeneron exec at bizjournals.com
11:00AM  Sarepta chief hands over CMO role to former Regeneron exec American City Business Journals
07:41AM  4 FDA Decisions to Watch Out for in Apr 2017
Mar-31-17 07:21AM  Pharma Stock Roundup: FDA Nod for SNY, Roche Drugs, Generic Advair Relief for GSK? Zacks
Mar-30-17 05:47PM  Trump's big pharma impact CNBC Videos
04:20PM  The 3 Best Cholesterol Drug Stocks to Buy in 2017 Motley Fool
01:09PM  Pharma Tests Preemptive Discounting Bloomberg
12:53PM  Eczema Drug Dupixent Reports Positive Survey Investopedia
10:12AM  Drugmakers Try New Strategy Amid Price Criticism: Charging Less Bloomberg
08:02AM  Regeneron's Game-Changing New Eczema Drug Could Be a Blockbuster Motley Fool
05:00AM  No One Prays for an iPhone, Says Drug Exec Slamming Trump Cuts
12:37AM  [$$] New and Improved Drug Prices May Lower Political Side Effects at The Wall Street Journal
Mar-29-17 01:35PM  [$$] New and Improved Drug Prices May Lower Political Side Effects at The Wall Street Journal
11:55AM  Sanofi Genzyme files preemptive legal strike to protect eczema drug at bizjournals.com
11:46AM  Regeneron Is Ready to Rally
10:21AM  Regeneron & Sanofi's Atopic Dermatitis Drug Gets FDA Nod
10:21AM  Regeneron & Sanofi's Atopic Dermatitis Drug Gets FDA Nod at Investopedia
08:30AM  Why investors arent more excited about Regenerons new $37,000-a-year drug at MarketWatch
08:15AM  Biotech Stock Roundup: Regeneron, Tesaro Drugs Approved, Vertex Scores Big in Study
08:15AM  Biotech Stock Roundup: Regeneron, Tesaro Drugs Approved, Vertex Scores Big in Study at Investopedia
Mar-28-17 04:38PM  Regeneron, Sanofi Get Approval For Eczema Drug Priced At $37,000
04:16PM  Regeneron, Sanofi Score Eczema Drug Approval
01:56PM  FDA approves Regeneron, Sanofi $37,000 per year eczema drug Reuters
01:50PM  Regeneron and Sanofi to Host Investor Conference Call to Discuss DUPIXENT® (dupilumab) Approval PR Newswire
11:57AM  Sanofi and Regeneron Announce FDA Approval of Dupixent® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis GlobeNewswire
11:54AM  Regeneron, Sanofi announce FDA approval of atopic dermatitis treatment at MarketWatch
11:40AM  Sanofi and Regeneron Announce FDA Approval of Dupixent® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis PR Newswire
11:40AM  Regeneron and Sanofi Announce FDA Approval of DUPIXENT® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis PR Newswire
11:38AM  FDA approves Regeneron, Sanofi eczema drug Reuters
Mar-27-17 03:22PM  Nasdaq Turns Positive; 3 Medicals To Watch; Will Snap Complete A Base?
Mar-26-17 06:43AM  3 Top Biotech Stocks to Buy in 2017 at Motley Fool
Mar-24-17 08:15AM  Regeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : REGN-US : March 24, 2017
07:47AM  Pharma Stock Roundup: Is Sanofi Buying Flexion? Pfizer, Merck KGaA Drug Approved
Mar-23-17 02:07PM  Regeneron, Sanofi Look To Crush Amgen, And Rivals Say They Can
Mar-22-17 08:01PM  [$$] DNA decoding initiative to involve 500,000 middle-aged Britons at Financial Times
08:01PM  GSK and Regeneron to mine gene data from 500,000 Britons
08:00PM  U.K. Biobank, Regeneron and GSK Announce Largest Gene Sequencing Initiative on World's Most Detailed Health Database to Improve Drug Discovery and Disease Diagnosis PR Newswire
Mar-21-17 12:33PM  Sanofi, Regeneron sue Amgen to protect eczema drug from patent claims
Mar-20-17 04:09PM  Esperion And Medicines Co. Recover From Amgen-Induced Pitfall
10:26AM  Amgen (AMGN): Repatha Outcomes Data Disappoint, Shares Drop
04:24AM  European Stocks Drift Lower; Deutsche Bank Falls on Rights Issue Details
03:00AM  European Stocks Set For Mixed Open: Dollar Slumps in Quiet Asia Trade
Mar-17-17 11:47PM  Amgens Repatha Study Shows Reduced Risk of Heart Attack, Stroke at The Wall Street Journal
07:18PM  Amgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke at The Wall Street Journal
04:59PM  The Biggest Loser: Amgen Drops 6.4% at Barrons.com
04:50PM  Esperion's Dive On Amgen Heart Study 'Counterintuitive' On Pricing
01:18PM  Here's Why Amgen, The Medicines Company, and Esperion Therapeutics Are All Tanking Today at Motley Fool
01:03PM  CVS Health says Amgen data may increase eligible patients by millions
11:22AM  Express Scripts says Amgen data opens door to patients
10:38AM  Amgen Cholesterol Drug Cuts Risk of Heart Attack, Stroke but Not Enough to Quell Value Debate
09:37AM  Amgen Tanks On Heart Study; Shares Of Other Drugmakers Tumble
09:14AM  Cholesterol drug cuts heart risks, spurs new debate on cost
08:48AM  What are Sanofi's (SNY) Strengths and Challenges in 2017?
06:29AM  Coverage initiated on Regeneron Pharma by Oppenheimer
Mar-16-17 05:52PM  Billion dollar boost for Amgen?
10:16AM  Ocular's Dextenza Reports Positive Study Results at Investopedia
Mar-15-17 02:48PM  Sanofi, Regenerons Dupilumab Gets UK Early Access at Investopedia
Mar-14-17 09:29PM  Teen Scientist Researches New Approach to Neurological Damage; Wins Regeneron Science Talent Search 2017 PR Newswire
10:35AM  Amgen's Repatha Meets Primary Endpoint in Phase III Study
Mar-13-17 04:37PM  Amgen Tops Heart Study As Rivals Regeneron, Sanofi Chill In Court
09:24AM  Amgen's Repatha lowers need for cholesterol-lowering procedure
01:00AM  Data on heart benefits of Amgen drug is key to unlocking sales
Mar-11-17 09:06AM  3 Growth Stocks I'd Buy Right Now at Motley Fool
Mar-10-17 12:35PM  Vetr Downgrades Regeneron Off Of Share Rise
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children's. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. The company also develops EYLEA, trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma. Regeneron Pharmaceuticals, Inc. has collaboration agreement with Sanofi for the development of antibody-based clinical products comprising Praluent, Sarilumab, Dupixent, REGN2810, REGN3500, and REGN3767; Bayer HealthCare LLC for the development of Nesvacumab/aflibercept, which is used in ophthalmology; and with Teva and Mitsubishi Tanabe Pharma Corporation for developing Fasinumab, an antibody to nerve growth factor, as well as collaboration agreement with Intellia Therapeutics, Inc., to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BROWN MICHAEL SDirectorMar 29Option Exercise177.821,000177,8201,000Mar 30 04:42 PM
BROWN MICHAEL SDirectorMar 29Sale400.001,000400,0000Mar 30 04:42 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 15Option Exercise20.32195,0793,964,005697,000Dec 19 04:09 PM
SCHLEIFER LEONARD SPresident & CEODec 15Option Exercise20.32250,0005,080,000292,806Dec 19 04:07 PM
BAKER CHARLES ADirectorDec 12Option Exercise18.613,00055,83012,000Dec 14 05:41 PM
BAKER CHARLES ADirectorDec 12Sale392.023,0001,176,0489,000Dec 14 05:41 PM
RYAN ARTHUR FDirectorNov 15Sale429.342,000858,68036,500Nov 16 04:21 PM
GOLDSTEIN JOSEPH LDirectorNov 14Option Exercise273.672,125581,54915,125Nov 15 04:08 PM
GOLDSTEIN JOSEPH LDirectorNov 14Sale450.002,125956,25013,000Nov 15 04:08 PM
VAGELOS P ROYChairman of the BoardNov 07Option Exercise20.3276,8951,562,506515,726Nov 09 04:10 PM
GOLDSTEIN JOSEPH LDirectorJul 29Option Exercise273.672,125581,54915,125Aug 01 04:04 PM
GOLDSTEIN JOSEPH LDirectorJul 29Sale425.002,125903,12513,000Aug 01 04:04 PM
RYAN ARTHUR FDirectorMay 24Sale396.641,000396,64039,500May 25 04:02 PM
Van Plew Daniel PEVP & General Mgr Industrial OMay 18Sale385.774,4131,702,4031,921May 19 04:26 PM
Van Plew Daniel PEVP & General Mgr Industrial OMay 17Option Exercise30.639,460289,76011,381May 19 04:26 PM
VAGELOS P ROYChairman of the BoardMay 12Option Exercise20.32230,6844,687,499563,564May 13 04:40 PM